Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients
Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients: a Randomized, Double-blind, Placebo Controlled, Superiority Trial
Phramongkutklao College of Medicine and Hospital
82 participants
Jan 31, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if drug montelukast works to treat dengue in adults. It will also learn about the safety of drug montelukast . The main questions it aims to answer are: Does drug montelukast lower the incidence of liver enzyme elevations in participants ? What medical problems do participants have when taking drug montelukast ?
Eligibility
Inclusion Criteria4
- Patient age >18 years
- Dengue infection diagnosed by NS1 antigen, or polymerase chain reaction
- Admitted to the hospital
- Written informed consent from patient or attending relative able to and willing to give informed consent
Exclusion Criteria11
- Other possible cause of fever other than dengue infection
- Pregnancy
- Unable to take medication
- Aminotransferase level above 150 U/l
- Allergy to paracetamol or tramadol
- Paracetamol indicated for condition other than dengue infection
- Critically ill patient who need ICU or invasive ventilation support
- History of cirrhosis
- Unable to communicate
- Other indication of montelukast
- History of psychiatric illness
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06747130